Table 5 hs-TnI of patients in H group and HP group under various risk factors.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
H group | HP group | P value | H group | HP group | P value | ||
|---|---|---|---|---|---|---|---|
N = 55 | N = 40 | N = 49 | N = 17 | ||||
Age ≥ 60 | CAD | ||||||
Baseline | 2.24 ± 1.87 | 2.31 ± 2.63 | 0.248 | Baseline | 1.64 ± 1.37 | 3.18 ± 2.49 | 0.009* |
3m | 2.89 ± 2.11 | 2.87 ± 2.82 | 0.654 | 3m | 1.90 ± 1.43 | 4.23 ± 2.86 | < 0.001* |
6m | 3.24 ± 2.46 | 3.53 ± 3.49 | 0.473 | 6m | 2.31 ± 1.28 | 4.96 ± 3.64 | 0.001* |
9m | 4.64 ± 3.23 | 3.59 ± 3.17 | 0.258 | 9m | 2.71 ± 1.45 | 5.55 ± 3.66 | < 0.001* |
12m | 4.43 ± 3.83 | 4.29 ± 3.65 | 0.755 | 12m | 2.35 ± 1.27 | 6.64 ± 3.87 | < 0.001* |
N = 91 | N = 95 | N = 184 | N = 110 | ||||
|---|---|---|---|---|---|---|---|
Left chest wall radiotherapy | Anthracyclines | ||||||
Baseline | 2.35 ± 1.59 | 2.22 ± 2.48 | 0.251 | Baseline | 2.52 ± 1.54 | 4.91 ± 3.83 | 0.043* |
3m | 2.97 ± 2.31 | 2.90 ± 2.95 | 0.629 | 3m | 3.29 ± 2.37 | 5.56 ± 2.97 | 0.028* |
6m | 3.65 ± 2.75 | 3.43 ± 3.57 | 0.432 | 6m | 3.96 ± 2.94 | 6.50 ± 3.74 | 0.006* |
9m | 4.53 ± 3.47 | 3.51 ± 3.26 | 0.205 | 9m | 4.78 ± 3.55 | 7.34 ± 3.93 | 0.008* |
12m | 4.58 ± 3.77 | 4.38 ± 3.53 | 0.856 | 12m | 4.93 ± 4.40 | 7.71 ± 3.70 | 0.001* |
